Journal of clinical monitoring and computing · 2025
Association of renal regional tissue oxygen saturation and post-procedural acute kidney injury following transcatheter aortic valve implantation.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lee Hoo Seung, Cho Youn Joung, Yoo Seungho, Lee Seohee, Ju Jae-Woo, Nam Karam, Jeon Yunseok
Аннотация
PURPOSE: Acute kidney injury (AKI) is a common complication and a strong risk factor for adverse outcomes after transcatheter aortic valve implantation (TAVI). Renal regional tissue oxygen saturation (rSO2) reflects tissue perfusion and can be measured using near-infrared spectroscopy. We hypothesized that decrease in renal rSO2 during TAVI would predict post-procedural AKI.
METHODS: Patients with severe aortic stenosis who scheduled for transfemoral TAVI were enrolled. Patients undergoing emergent procedures, those with severe renal impairment, those with a distance from skin to renal capsule > 4 cm, those on mechanical ventilation, or those who refused to participate were excluded. The primary outcome was the relationship between changes in renal rSO2 during TAVI and post-procedural AKI. AKI was determined according to the Valve Academic Research Consortium-2 criteria.
RESULTS: Sixty-four patients were included and analyzed. The mean (standard deviation [SD]) age of patients was 82 (4) years, and the median [interquartile range] procedure time was 75 [65-90] min. The incidence of post-procedural AKI was 33% (21/64). There was no difference in the mean (SD) time-weighted renal rSO2 (70% [13%] and 73% [11%]), changes in renal rSO2 (-14% [10%] and - 15% [13%]), or nadir rSO2 (55% [17%] and 60% [17%]) during TAVI between patients who developed post-TAVI AKI and those who did not (p = 0.227, 0.157, and 0.333, respectively). In multivariable regression analysis, renal rSO2 variables were not predictors of post-TAVI AKI.
CONCLUSION: Procedural changes in renal rSO2 measured using near-infrared spectroscopy did not predict the development of post-TAVI AKI. Further studies are needed to investigate more effective strategies to predict and prevent AKI following TAVI.
TRIAL REGISTRATION: This study was registered on cinicaltrials.gov (identifier, NCT04921475, registered on June 10, 2021).
METHODS: Patients with severe aortic stenosis who scheduled for transfemoral TAVI were enrolled. Patients undergoing emergent procedures, those with severe renal impairment, those with a distance from skin to renal capsule > 4 cm, those on mechanical ventilation, or those who refused to participate were excluded. The primary outcome was the relationship between changes in renal rSO2 during TAVI and post-procedural AKI. AKI was determined according to the Valve Academic Research Consortium-2 criteria.
RESULTS: Sixty-four patients were included and analyzed. The mean (standard deviation [SD]) age of patients was 82 (4) years, and the median [interquartile range] procedure time was 75 [65-90] min. The incidence of post-procedural AKI was 33% (21/64). There was no difference in the mean (SD) time-weighted renal rSO2 (70% [13%] and 73% [11%]), changes in renal rSO2 (-14% [10%] and - 15% [13%]), or nadir rSO2 (55% [17%] and 60% [17%]) during TAVI between patients who developed post-TAVI AKI and those who did not (p = 0.227, 0.157, and 0.333, respectively). In multivariable regression analysis, renal rSO2 variables were not predictors of post-TAVI AKI.
CONCLUSION: Procedural changes in renal rSO2 measured using near-infrared spectroscopy did not predict the development of post-TAVI AKI. Further studies are needed to investigate more effective strategies to predict and prevent AKI following TAVI.
TRIAL REGISTRATION: This study was registered on cinicaltrials.gov (identifier, NCT04921475, registered on June 10, 2021).